Loading...
OTCM
CVSI
Market cap4mUSD
Dec 02, Last price  
0.03USD
1D
-8.77%
1Q
-35.00%
Jan 2017
-93.95%
IPO
-99.49%
Name

CV Sciences Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
0.31
EPS
Div Yield, %
Shrs. gr., 5y
12.40%
Rev. gr., 5y
-21.80%
Revenues
16m
-1.87%
002,154,06310,190,66711,529,40211,060,63620,679,23948,244,00053,696,00024,429,00020,048,00016,205,00016,004,00015,705,000
Net income
-2m
L
-90,180-45,611-2,300,196-1,311,951-12,233,128-14,141,298-4,897,13910,001,000-16,610,000-22,284,000-15,554,000-8,214,0003,102,000-2,394,000
CFO
-861k
L
-79,632-64,084-4,879,234-6,711,999-4,208,267-2,053,7403,615,00412,559,000-2,138,000-7,300,000-7,485,000-1,885,0002,253,000-861,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
IPO date
Oct 04, 2018
Employees
42
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT